BioWorld - Monday, April 20, 2026

Articles Tagged with ''siRNA''

Squamous cell carcinoma.

Sirnaomics advances siRNA skin cancer candidate to late-stage trials

June 20, 2023
By Tamra Sami
Sirnaomics Ltd. is advancing lead siRNA candidate STP-705 for the treatment of squamous cell carcinoma in situ into late-stage clinical testing after sharing encouraging phase II trial results with the U.S. FDA in an end-of-phase II meeting. The company plans to move forward in 2023 with a single-dose study as a subgroup of subjects in a large phase III study. Positive results will provide the basis for completion of this large registrational phase III trial.
Read More
Liver and DNA
Newco news

Cargene’s siRNA therapy has potential to regenerate the liver and reverse fibrosis

Feb. 21, 2023
By Tamra Sami
One of the most important transformations in the pharmaceutical industry over the next decade is the ability to modify genes or expression and go after any target, Cargene Biopharma Inc. CEO Kathy He told BioWorld, explaining that small molecules and large molecules can only go after 15% of the known targets. But the technology platform of short-interfering RNA (siRNA) opens a huge opportunity to make those inaccessible targets available, she said.
Read More
Liver and DNA
Newco news

Cargene’s siRNA therapy has potential to regenerate the liver and reverse fibrosis

Feb. 17, 2023
By Tamra Sami
One of the most important transformations in the pharmaceutical industry over the next decade is the ability to modify genes or expression and go after any target, Cargene Biopharma Inc. CEO Kathy He told BioWorld, explaining that small molecules and large molecules can only go after 15% of the known targets. But the technology platform of short-interfering RNA (siRNA) opens a huge opportunity to make those inaccessible targets available, she said.
Read More

Sirnaomics seeks FDA guidance for late-stage skin cancer candidate

Feb. 1, 2023
By Caroline Richards
Sirnaomics Ltd. is gearing up to start either an expanded phase IIb or a phase III clinical trial for its lead siRNA candidate, STP-705, for the treatment of two non-melanoma skin cancers: squamous cell carcinoma in situ and basal cell carcinoma. STP-705 comprises two siRNA oligonucleotides that inhibit transforming growth factor beta 1 and cyclooxygenase-2 gene expressions and is delivered via injection using what the company describes as a polypeptide nanoparticle-enhanced delivery mechanism.
Read More